← All trials
NCT05905172
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2023
- Primary completion
- Jun 20, 2028
- Completion date
- Oct 20, 2028
- First posted
- Jun 15, 2023
- Last posted
- Jun 18, 2023
- Enrollment
- 248
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GNI GroupLead sponsor
- Capital Medical UniversityOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.